Furthermore, according to the results of ECOG1505 trial, there was no significant difference between the adjuvant chemotherapy with or without bevacizumab for patients with resected NSCLC.46 One of the reasons to explain these negative results might be the heterogeneity in the expression of vascular endothelial growth factor (VEGF). The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.